However, a large variety of different EGFR mutant alleles have been identified in NSCLC patients, and it is becoming increasingly clear that different EGFR mutants may vary dramatically in their sensitivity or resistance to TKIs [15,31-33]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.